Rova-T<\/em> by AbbVie<\/strong>, anticancer. Peak sales forecast of $1.44 billion\/year dollars in cash and up to an additional $4 billion upon meeting goals). The drug has demonstrated encouraging antitumor activity combined with a manageable safety profile in a recent Phase 1 study. It works by releasing a cytotoxic "bomb" directly on DLL3 proteins, normally expressed by cancer cells in the 80% of patients with this type of tumor, and absent in healthy cells.<\/p>\n5) Ozanimod<\/em> \u00a0of Celgene<\/strong>against multiple sclerosis. Peak sales forecast: $1.27 billion\/year. It is a novel orally active, selective sphingosine 1-phosphate 1 (S1PR1) and 5-phosphate (S1PR5) receptor modulator in development for immuno-inflammatory indications, including relapsing multiple sclerosis, ulcerative colitis, and Crohn's. It belongs to the same class of fingolimod, but characterized by improved security.<\/p>\n6) Apalutamide <\/em>by Johnson & Johnson<\/strong>, anticancer, peak sales forecast: $1.24 billion\/year. It is a next-generation oral androgen receptor blocker for non-metastatic castration-resistant prostate cancer (CRPC), for which Janssen filed an FDA approval application in October. The first drug for this clinical setting, it works by inhibiting the action of testosterone in cancer cells and preventing androgens from binding to the specific receptor. Prostate cancer is the most common cancer among American men, along with skin cancer. More than 161,000 cases of prostate cancer are expected to be diagnosed in 2017. It has been estimated that 10-20% of patients diagnosed with prostate cancer may develop CRPC within 5 years. The global market for prostate cancer drugs is estimated to reach US$12 billion by 2025.<\/p>\n7) \u00a0Elagolix<\/em> \u00a0by AbbVie<\/strong>, against pain associated with endometriosis. Peak sales forecast: $1.21 billion\/year. It is an oral gonadotropin-releasing hormone (GnRH) antagonist and is being developed for the treatment of moderate to severe endometriosis pain, a condition that affects one in ten women of reproductive age and is associated with painful symptoms that can be debilitating.
\nThe application for approval was filed with the FDA last September and, if accepted, will Elagolix<\/em> the first treatment option for the treatment of pain associated with endometriosis in over a decade.<\/p>\n8) AVXS-101<\/em> by Avexis,<\/strong> drug for the treatment of spinal muscular atrophy (MSA, a rare disease), with peak sales forecast of $1.14 billion. Got the
\ndesignation of breakthrough therapy<\/em>y, as well as the designation fast track<\/em>for the treatment of Type 1 AMS, one of the most serious genetic neurological disorders.
\nSpinal muscular atrophy is a serious neuromuscular disease caused by a genetic defect in the SMN1 gene, leading to the loss of motor neurons and causing progressive muscle weakness and paralysis. AVXS-101<\/em> will compete directly with the new drug Spinraza<\/em> by Biogen which, at a price of 750,000 dollars for the first year of treatment, is one of the 10 most expensive therapies in the world.<\/p>\n9) Lanadelumab<\/em> \u00a0of Shire<\/strong>, a monoclonal antibody targeting plasma kallikrein, involved in the etiopathogenesis of hereditary angioedema (HAE) or Quincke's angioedema, a rare disease characterized by recurrent swelling of the skin, mucous membranes and internal organs which can sometimes be fatal. Peak sales forecast: $1.12 billion\/year
\nThere are only very few drugs to treat HAE attacks and its symptoms and Shire has most of them, having Cynryze<\/em> (human C1-inhibitor), Firazyr <\/em>(icatibant) e kalbito<\/em>r (ecallantis).
\nLanadelumab<\/em> it is the result of the purchase by Shire (for 5.9 billion dollars) of Dyax, which had developed the drug, of particular interest due to the mechanism of action which differs from that of already available drugs.<\/p>\n10 Epidiolex<\/em> \u00a0by GW Pharma<\/strong>, a non-psychoactive cannabinoid, developed for the treatment of seizures in two specific types of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. The peak sales forecast is $960 million. It is a liquid formulation of purified cannabidiol of plant origin, whose dossier was filed with the FDA for approval on October 30, accompanied by clinical data on 1,500 patients, 400 of whom had more than a year of drug exposure.
\nGW Pharma expects "significant demand" from the Lennox-Gastaut and Dravet patient populations, which total approximately 35,000 and 8,000 patients, respectively. There are currently no licensed treatments in the United States for Dravet syndrome.
\nThe positive results of the recent phase 3 study on Epidiolex<\/em> represent the only well-controlled clinical evaluation of a cannabinoid drug for this devastating, drug-resistant condition.<\/p>","protected":false},"excerpt":{"rendered":"Roma, 18 dicembre \u2013 Nuovi farmaci contro l\u2019Hiv e il diabete, ma soprattutto terapie antitumorali e per le malattie rare: appartengono a queste categorie, secondo le stime degli analisti della societ\u00e0 di intelligence di mercato EvaluatePharma, i dieci farmaci che nel 2018 arriveranno probabilmente a generare vendite annuali superiori al miliardo di dollari. RIF day …<\/p>","protected":false},"author":4,"featured_media":31975,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[47,26],"class_list":["post-33966","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-big-pharma","tag-spesa-farmaceutica"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/33966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=33966"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/33966\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/31975"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=33966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=33966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=33966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\"](\"http:\/\/www.fedaiisf.it\/wp-content\/uploads\/2015\/05\/gilead-300x179.jpg\")
<\/a>1) Bictegravir\/FTC\/TAF<\/em>\u00a0 of Gilead, <\/strong>an anti-HIV drug whose peak sales are expected to be 5.05 billion dollars\/year. It is a fixed-dose combination of bictegravir (Bic) and emtricitabine\/tenofovir alafenamide (FTC\/TAF) indicated for the treatment of HIV-1 infection in treatment-na\u00efve adults. Received the priority review<\/em> of the FDA.<\/p>\n![\"\"](\"http:\/\/www.fedaiisf.it\/wp-content\/uploads\/2014\/07\/abbvie.jpg\")
<\/a>4) Rova-T<\/em> by AbbVie<\/strong>, anticancer. Peak sales forecast of $1.44 billion\/year dollars in cash and up to an additional $4 billion upon meeting goals). The drug has demonstrated encouraging antitumor activity combined with a manageable safety profile in a recent Phase 1 study. It works by releasing a cytotoxic "bomb" directly on DLL3 proteins, normally expressed by cancer cells in the 80% of patients with this type of tumor, and absent in healthy cells.<\/p>\n